electroCore, Inc. (ECOR)

electroCore's stock price has fluctuated over the past six months. As of March 18, 2026, the share price was $6.90, a 13.86% decline from March 19, 2025. The stock decreased by 73.71% over the last 12 months, and by 1.87% in the past month, as of January 5, 2026. Recent events include the announcement of full-year 2025 financial results with record net sales of $32.0 million, the retirement of CEO Daniel Goldberger, and preliminary full-year 2025 business updates anticipating record revenue of approximately $31.8 - $32.0 million.

The provided information does not explicitly indicate any specific seasonality in the demand for electroCore's products and services. Demand for prescription devices in the U.S. is influenced by clinical data and the company's increased presence in the field, while international demand is driven by clinical and health economic data.

electroCore, Inc. is a medical technology company focused on bioelectronic medicine and wellness, specializing in non-invasive vagus nerve stimulation (nVNS) technology. Their products include gammaCore and gammaCore Sapphire, prescription devices for headache treatment; Quell Fibromyalgia, a neurostimulator for fibromyalgia symptoms; and Truvaga and TAC-STIM, consumer products for general wellness.

electroCore, Inc. is headquartered in Rockaway, New Jersey, United States. The company provides its nVNS technology platform in the United States, the United Kingdom, and internationally. A significant portion of its revenue comes from government and health-system customers, with U.S. Department of Veterans Affairs facilities generating 71.2% of its 2025 revenue and U.K. NHS sales contributing 4.4% under the MedTech Funding Mandate.

electroCore has strengthened its brand reputation through intellectual property expansion, including the issuance of two new U.S. patents related to nVNS technology. Potential negative impacts on reputation could arise from cybersecurity risks.

electroCore, Inc. has a mix of institutional and individual owners. Major institutional shareholders include Vanguard Group Inc, Tejara Capital Ltd, and International Assets Investment Management, Llc. Key individual shareholders include Joseph P. Errico, James L. L. Tullis, and Thomas J. Errico. Merck Global Health Innovation Fund LLC and Core Ventures II LLC are also notable owners.